TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32719055
Drug: As-needed combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: As-needed combination preventer and reliever therapy
Study: 32719055
Drug: Maintenance budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Maintenance budesonide plus terbutaline reliever therapy
Study: 34994269
Drug: Triple Pill
Normalized name: Triple Wormer Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple Pill (telmisartan 20 mg, amlodipine 2.5 mg, indapamide 1.25 mg)
Study: 36165681
Drug: Intralesional HBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional HBV vaccine
Study: 36165681
Drug: Intramuscular HBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular HBV vaccine
Study: 33351153
Drug: Focused extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Focused extracorporeal shock wave therapy
Study: 32816255
Drug: Individual empowerment
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual empowerment and knowledge of treatment benefits
Study: 34223253
Drug: Recombinant follicle-stimulating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant follicle-stimulating hormone (FSH)
Study: 38905580
Drug: Topical capsaicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical capsaicin
Study: 35910068
Drug: 0.2 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 μg/kg of sufentanil
Study: 35582945
Drug: Client‐centred activities
Approvals — FDA: no, EMA: no, PMDA: no
Description: Client‐centred activities of daily living (CADL) intervention
Study: 32986904
Drug: Action Observation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Action Observation Therapy (AOT) - observation of uni/bimanual goal-directed actions followed by execution
Study: 33545483
Drug: High levels
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High levels of serum BPA (2.92 ng/mL)
Study: 32068423
Drug: Cognitive AS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive AS treatment
Study: 36109825
Drug: Dexamethasone (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (6 mg once daily for 7 days)
Study: 36246990
Drug: High-dose Dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Dexmedetomidine
Study: 36246990
Drug: Medium-dose Dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose Dexmedetomidine
Study: 36246990
Drug: Low-dose Dexmedetomidine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Dexmedetomidine
Study: 34755269
Drug: Colchicine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (1.5 mg at baseline and 0.5 mg BID PO for 10 days)
Study: 34052927
Drug: Active photobiomodulation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active photobiomodulation (PBM) treatment (pulsed near-infrared 808 nm Ga-Al-As laser, 250 mW, 8.8 J/cm2) for up to 12 weeks in addition to standard care
Study: 34865002
Drug: Treatment arms
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment arms (not specified)
Study: 32542370
Drug: Placebo (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (100 ml saline)
Study: 33601334
Drug: Weekly feedback
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly feedback
Study: 32536056
Drug: Fuzheng Huayu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fuzheng Huayu capsule
Study: 33863614
Drug: Supervised formal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised formal physical therapy (PT)
Study: 33396496
Drug: Creative Music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creative Music Therapy (CMT)
Study: 32468719
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg fingolimod HCl capsule (Lebrina)
Study: 32468719
Drug: Both formulations
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both formulations of fingolimod
Study: 35685899
Drug: basic treatment
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: basic treatment + electroacupuncture
Study: 34309987
Drug: Melissa officinalis
Normalized name: melissa officinalis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melissa officinalis tea (MO tea), 2-g dried leaves/250 mL in hot water, two times/day for 12 weeks, in addition to lifestyle modification recommendations.
Study: 33059801
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin D3 drops (900 IU/d) for 25 days
Study: 32189338
Drug: Pregabalin 14
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin 14 mg/kg/d
Study: 36233538
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (low-intensity exercise without TJ‐41 treatment) for 12 weeks
Study: 37042545
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg rizatriptan
Study: 34706567
Drug: Physiologic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiologic saline solution
Study: 34342012
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) for 12 weeks
Study: 33243030
Drug: Metformin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin treatment (2 g/day)
Study: 34364737
Drug: Mulabandha yoga
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mulabandha yoga therapy (MYT) for 12 weeks
Study: 35123664
Drug: Probiotic and
Normalized name: Florastor Advanced Probiotic And Digestive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic and peanut oral immunotherapy (PPOIT)
Study: 32311780
Drug: Lipegfilgrastim (LIPEG)
DrugBank: Lipegfilgrastim (DB13200)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Lipegfilgrastim (LIPEG) 6 mg
Study: 33345452
Drug: SGLT2 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SGLT2 inhibitors (75% adoption)
Study: 32534376
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (30 mg elemental zinc)
Study: 32961802
Drug: SVF injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: SVF injection
Study: 35112890
Drug: ivabradine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ivabradine (5 mg BID, 1-week)
Study: 33269798
Drug: Sinovac EV71
Normalized name: COVID-19 IV Non-US Vaccine (CoronaVac, Sinovac)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinovac EV71 vaccine
Study: 33271095
Drug: Gemogenovatucel-T (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemogenovatucel-T (1 × 10^7 cells per injection), administered intradermally (one per month) for a minimum of four and up to 12 doses.
Study: 33271095
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered intradermally (one per month) for a minimum of four and up to 12 doses.
Study: 33713335
Drug: Self-esteem group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-esteem group with treatment as usual (TAU)
Study: 33094848
Drug: Home enteral
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home enteral and parenteral nutrition support
Study: 34092255
Drug: Topical high-linoleate
Normalized name: linoleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical high-linoleate sunflower seed oil (SSO) applied at 3 g/kg three times daily for 10 days
Study: 34092255
Drug: Topical high-linoleate
Normalized name: linoleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical high-linoleate sunflower seed oil (SSO)
Study: 34663681
Drug: 3-minute high-intensity
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-minute high-intensity interval exercise program (jumps, squats, various steps) implemented twice weekly over 10 weeks for 10 to 25 minutes per session
Study: 34482350
Drug: F/TAF 200 mg/25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: F/TAF 200 mg/25 mg
Study: 34482350
Drug: F/TDF 200 mg/300 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: F/TDF 200 mg/300 mg
Study: 32089078
Drug: 12-session weekly
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-session weekly yoga intervention
Study: 33287836
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment in PCOS patients (PCOS-GH)
Study: 36263739
Drug: Osmotic-release oral
Normalized name: nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Osmotic-release oral system methylphenidate (OROS-methylphenidate)
Study: 35948418
Drug: OPEP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPEP therapy using Acapella device for 3 months
Study: 34936265
Drug: Suspension training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension training
Study: 35623878
Drug: Intravenous 2
Normalized name: Premarin Intravenous 25 MG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 2 g of vitamin C in normal saline
Study: 35623878
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline therapy (control)
Study: 34503460
Drug: Skull remodeling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skull remodeling surgery, Tumor Treating Fields therapy (TTFields), and best practice oncology
Study: 34503460
Drug: Tumor Treating
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumor Treating Fields therapy (TTFields) and best physicians choice oncological treatment (control arm)
Study: 32618829
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (MgSO4) 300 mg daily for 6 months
Study: 35871083
Drug: Low-dose Neu2000K
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Neu2000K
Study: 35871083
Drug: High-dose Neu2000K
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Neu2000K
Study: 32682962
Drug: Guideline directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline directed medical therapy (GDMT)
Study: 36210809
Drug: Mesalazine (4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalazine (4.0 g/d, once a day for 3 months)
Study: 33945920
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care (PC) group
Study: 34481420
Drug: Photobiomodulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation therapy (PBM) combined with standard skincare (2x/week) during the complete radiotherapy course
Study: 34184795
Drug: On-line self-help
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-line self-help intervention consisting of 10 modules based on cognitive-behavioral therapy and motivational interviewing.
Study: 36342972
Drug: DPP-4 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DPP-4 inhibitors
Study: 39608381
Drug: GLP-1 receptor
Normalized name: GLP-1 receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 receptor agonists
Study: 32664094
Drug: Intravenous normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous normal saline (control group)
Study: 33063610
Drug: Histamine H3
Normalized name: Histamine H3 receptor antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine H3 receptor gene variant (rs13042865)
Study: 34248041
Drug: Standard dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dosage of terlipressin
Study: 34248041
Drug: Modified dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified dose of terlipressin
Study: 38250270
Drug: Mindfulness Based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness Based Cognitive Therapy (MBCT)
Study: 39055495
Drug: Capecitabine monotherapy
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine monotherapy
Study: 34616489
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg plus best supportive care (BSC)
Study: 35771645
Drug: Taper period
Normalized name: caper berry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taper period after intensified training
Study: 34497078
Drug: Adjunctive use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive use of an internet-based self-management intervention (priovi)
Study: 35267951
Drug: Behavioral weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral weight loss (BWL) treatment for 4 months
Study: 37344262
Drug: PCV13 (13-valent
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCV13 (13-valent pneumococcal conjugate vaccine)
Study: 35146039
Drug: PPSV23 (23-valent
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPSV23 (23-valent pneumococcal polysaccharide vaccine)
Study: 37021410
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ezetimibe (EZE) tablets (test product)
Study: 37021410
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ezetimibe (EZE) tablets (reference product)
Study: 35695720
Drug: Paliperidone ER
Normalized name: Paliperidone ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paliperidone ER (6-15 mg/d)
Study: 35695720
Drug: Olanzapine (10-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (10-30 mg/d)
Study: 34023351
Drug: Glecaprevir/pibrentasvir (G/P)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glecaprevir/pibrentasvir (G/P) for 12 or 16 weeks
Study: 34023351
Drug: Glecaprevir/pibrentasvir (G/P)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glecaprevir/pibrentasvir (G/P) with ribavirin for 12 weeks
Study: 34023351
Drug: Treatment-emergent NS5A
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-emergent NS5A RASs
Study: 34930979
Drug: Tenoten (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoten (8 tablets/day)
Study: 35947279
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of BFT and dapoxetine 30 mg
Study: 33536096
Drug: Oily fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oily fish consumption (about 300 g/week for 12 weeks)
Study: 32638463
Drug: Intralesional injection
Normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional injection of botulinum toxin type A once a month for 4 months
Study: 34404237
Drug: Clopidogrel-monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel-monotherapy
Study: 34404237
Drug: DAPT using
Normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAPT using cilostazol and aspirin
Study: 33119477
Drug: Control group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group: pelvic radiation of 50 Gy/25 fractions with concurrent capecitabine, followed by oxaliplatin and capecitabine
Study: 35876837
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light therapy (BLT) for 30 minutes in the morning at 10,000 lux for 6 weeks
Study: 38195732
Drug: Non-surgical periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical periodontal therapy (NSPT)
Study: 35184691
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose intravenous cefuroxime after cord clamping (n=19)
Study: 35184691
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose intravenous cefuroxime 30 minutes before skin incision (n=21)
Study: 35811518
Drug: Personalized, precision
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized, precision medicine protocol for nine months
Study: 34391239
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (non-therapeutic gel with light touch for 3min)
Study: 33532013
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg amitriptyline at bedtime
Study: 33722585
Drug: Quadrivalent high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent high-dose influenza vaccine (QIV-HD)
Study: 39303788
Drug: Standard-dose quadrivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose quadrivalent influenza vaccine (QIV-SD)
Study: 36181316
Drug: PegIFN‐α monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PegIFN‐α monotherapy (180 μg/week)
Study: 33633016
Drug: 1% Phentolamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% Phentolamine mesylate ophthalmic solution (PMOS)
Study: 33633016
Drug: 1% Phentolamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% Phentolamine mesylate ophthalmic solution (PMOS) in the tropicamide subgroup
Study: 34726625
Drug: Immediate neoadjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate neoadjuvant instillation of chemotherapy (INAIC) with mitomycin C before TURBT (Group A)
Study: 32366224
Drug: Lidocaine/prilocaine cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine/prilocaine cream (2 g applied to the tracheal tube cuff)
Study: 32366224
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Vaseline 2 g applied to the tracheal tube cuff)
Study: 37041561
Drug: EIT-guided PEEP
Normalized name: 2,2',3,3',4,4',5,5',6-nonachlorodiphenyl either
Approvals — FDA: no, EMA: no, PMDA: no
Description: EIT-guided PEEP titration
Study: 35887937
Drug: Intensive periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive periodontal treatment
Study: 32795875
Drug: 70-gene signature
Normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 70-gene signature (MammaPrint®) guided treatment strategy
Study: 34709369
Drug: Low-dose CT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CT of the chest
Study: 32486583
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose of levosimendan (0.1 μg·kg(‐1)·min(‐1) for 24 h after loading with 6 μg/kg)
Study: 32486583
Drug: Maintenance dose
Normalized name: Firmagon 80mg Powder for Injection Maintenance Dose Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance dose of levosimendan (same schedule without loading dose)
Study: 35869311
Drug: Concentrated beetroot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentrated beetroot juice (BJ) 24 ml daily for 12 weeks
Study: 35109906
Drug: Topical fusidic
Normalized name: fusidate Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical fusidic acid
Study: 35871071
Drug: Combined HCQ
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined HCQ treatment periods
Study: 35871071
Drug: Combined placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined placebo treatment periods
Study: 34288591
Drug: Home infusions
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home infusions of natalizumab (n=18)
Study: 32781869
Drug: sl‐wIRAR treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: sl‐wIRAR treatment (2 treatments for 30 min per day for 6 days)
Study: 34602460
Drug: sl‐wIRAR treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: sl‐wIRAR treatment
Study: 32781869
Drug: NSAID therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAID therapy reduction
Study: 38315944
Drug: Physician's choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician's choice chemotherapy
Study: 39665235
Drug: Pindolol 30
Normalized name: Pindolol
DrugBank: Pindolol (DB00960)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pindolol 30 mg
Study: 33021110
Drug: Zonisamide as
Normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Zonisamide as an adjunctive treatment to levodopa
Study: 37115133
Drug: Polypharmacy (≥5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polypharmacy (≥5 medications excluding HFrEF GDMT) at baseline
Study: 37115133
Drug: No polypharmacy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No polypharmacy (<5 medications) at baseline
Study: 36088609
Drug: Luminor® 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luminor® 35 drug‐coated balloon (DCB) angioplasty
Study: 32584155
Drug: AKL-T03 (videogame-like
Approvals — FDA: no, EMA: no, PMDA: no
Description: AKL-T03 (videogame-like digital treatment)
Study: 34223734
Drug: 20 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg Genistein (GEN)
Study: 33713484
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline injection
Study: 36584579
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline injection
Study: 32749733
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy only (Control)
Study: 36308446
Drug: Anticoagulated group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulated group (warfarin + aspirin)
Study: 36308446
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (aspirin only)
Study: 34597899
Drug: Sepranolone 10
Normalized name: Sepranolone
DrugBank: Sepranolone (DB12972)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sepranolone 10 mg
Study: 34597899
Drug: Sepranolone 16
Normalized name: Sepranolone
DrugBank: Sepranolone (DB12972)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sepranolone 16 mg
Study: 32464527
Drug: CLIP intervention
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CLIP intervention (community engagement, community health worker-provided mobile health-guided clinical assessment, initial treatment, and referral)
Study: 35468266
Drug: Group-based outpatient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based outpatient physical therapy delivered 6 weeks after TKR, costing £179 ± 39 per patient.